BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 27009237)

  • 1. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
    Szabo E; Schneider H; Seystahl K; Rushing EJ; Herting F; Weidner KM; Weller M
    Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
    Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
    Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
    Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades.
    Lee JH; Choi S; Lee Y; Lee HJ; Kim KH; Ahn KS; Bae H; Lee HJ; Lee EO; Ahn KS; Ryu SY; Lü J; Kim SH
    Mol Cancer Ther; 2010 Feb; 9(2):389-99. PubMed ID: 20103598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells.
    Mac Gabhann F; Popel AS
    Am J Physiol Heart Circ Physiol; 2004 Jan; 286(1):H153-64. PubMed ID: 12714333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
    Zhang Q; Yu C; Peng S; Xu H; Wright E; Zhang X; Huo X; Cheng E; Pham TH; Asanuma K; Hatanpaa KJ; Rezai D; Wang DH; Sarode V; Melton S; Genta RM; Spechler SJ; Souza RF
    Gastroenterology; 2014 Feb; 146(2):461-72.e6. PubMed ID: 24120473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.
    Knizetova P; Ehrmann J; Hlobilkova A; Vancova I; Kalita O; Kolar Z; Bartek J
    Cell Cycle; 2008 Aug; 7(16):2553-61. PubMed ID: 18719373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
    Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S
    PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
    Hamerlik P; Lathia JD; Rasmussen R; Wu Q; Bartkova J; Lee M; Moudry P; Bartek J; Fischer W; Lukas J; Rich JN; Bartek J
    J Exp Med; 2012 Mar; 209(3):507-20. PubMed ID: 22393126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma.
    Ohba T; Cates JM; Cole HA; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
    Mol Cancer Res; 2014 Aug; 12(8):1100-11. PubMed ID: 24759089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.
    D'Alessio A; Proietti G; Lama G; Biamonte F; Lauriola L; Moscato U; Vescovi A; Mangiola A; Angelucci C; Sica G
    Oncotarget; 2016 Nov; 7(48):78541-78556. PubMed ID: 27705944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.
    Farzaneh Behelgardi M; Zahri S; Gholami Shahvir Z; Mashayekhi F; Mirzanejad L; Asghari SM
    Mol Biol Rep; 2020 Mar; 47(3):2061-2071. PubMed ID: 32072404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.